HUP0300559A2 - A trombopoietin receptort moduláló peptidek - Google Patents

A trombopoietin receptort moduláló peptidek

Info

Publication number
HUP0300559A2
HUP0300559A2 HU0300559A HUP0300559A HUP0300559A2 HU P0300559 A2 HUP0300559 A2 HU P0300559A2 HU 0300559 A HU0300559 A HU 0300559A HU P0300559 A HUP0300559 A HU P0300559A HU P0300559 A2 HUP0300559 A2 HU P0300559A2
Authority
HU
Hungary
Prior art keywords
receptor modulating
thrombopoietin receptor
modulating peptide
peptide
thrombopoietin
Prior art date
Application number
HU0300559A
Other languages
English (en)
Inventor
Tatjana Naranda
Lennart Olsson
Original Assignee
Pliva, Farmaceutska Industrija, Dionicko Drustvo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva, Farmaceutska Industrija, Dionicko Drustvo filed Critical Pliva, Farmaceutska Industrija, Dionicko Drustvo
Publication of HUP0300559A2 publication Critical patent/HUP0300559A2/hu
Publication of HUP0300559A3 publication Critical patent/HUP0300559A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A találmány tárgyát új diagnosztikai és gyógyászati készítményekképezik, amik lehetővé teszik a trombocitopénia kezelését. Ó
HU0300559A 2000-04-25 2001-04-23 Thrombopoietin receptor modulating peptide HUP0300559A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108075A EP1149906A1 (en) 2000-04-25 2000-04-25 Thrombopoietin receptor modulating peptide
PCT/EP2001/004553 WO2001080873A2 (en) 2000-04-25 2001-04-23 Thrombopoietin receptor modulating peptide

Publications (2)

Publication Number Publication Date
HUP0300559A2 true HUP0300559A2 (hu) 2003-06-28
HUP0300559A3 HUP0300559A3 (en) 2005-09-28

Family

ID=8168467

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300559A HUP0300559A3 (en) 2000-04-25 2001-04-23 Thrombopoietin receptor modulating peptide

Country Status (24)

Country Link
US (1) US20030181659A1 (hu)
EP (2) EP1149906A1 (hu)
JP (1) JP2003530867A (hu)
KR (1) KR20030009450A (hu)
CN (1) CN1426467A (hu)
AR (1) AR030278A1 (hu)
AU (2) AU6736601A (hu)
BG (1) BG107214A (hu)
BR (1) BR0110383A (hu)
CA (1) CA2407167A1 (hu)
CZ (1) CZ20023517A3 (hu)
EA (1) EA006423B1 (hu)
EE (1) EE200200610A (hu)
GE (1) GEP20063763B (hu)
HU (1) HUP0300559A3 (hu)
IL (1) IL152204A0 (hu)
IS (1) IS6582A (hu)
MX (1) MXPA02010458A (hu)
NO (1) NO20025114L (hu)
PL (1) PL358304A1 (hu)
SK (1) SK15262002A3 (hu)
WO (1) WO2001080873A2 (hu)
YU (1) YU79202A (hu)
ZA (1) ZA200208662B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002359362A1 (en) * 2001-11-07 2003-05-19 Millennium Pharmaceuticals, Inc. Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
US7923431B2 (en) * 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
ES2462916T3 (es) * 2002-09-18 2014-05-26 Janssen Pharmaceuticals, Inc. Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
CN1739017B (zh) 2002-12-11 2011-04-06 弗罗桑医疗设备公司 用作拭子的基于明胶的材料
EP2204193A3 (en) * 2003-05-12 2010-08-18 Affymax, Inc. Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds
CN1820024B (zh) * 2003-05-12 2011-06-22 阿费麦克斯公司 新的聚(乙二醇)修饰的化合物及其用途
JP2005187435A (ja) * 2003-12-26 2005-07-14 Otsuka Chemical Co Ltd 血小板産生促進組成物
WO2005072700A2 (en) 2004-01-30 2005-08-11 Ferrosan A/S Haemostatic sprays and compositions
CN101001649B (zh) 2004-07-09 2011-08-31 弗罗桑医疗设备公司 包括透明质酸的止血组合物及其制备方法
CA2641189A1 (en) * 2006-01-31 2007-08-09 Mitsubishi Kagaku Iatron, Inc. Method for determination of condition of disseminated intravascular coagulation syndrome
EP2259803B2 (en) 2008-02-29 2019-03-13 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
ES2659262T3 (es) * 2011-05-13 2018-03-14 The University Of Tokyo Célula megacariocítica polinucleada y método para la elaboración de plaquetas
CA2865349C (en) 2012-03-06 2021-07-06 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
CA2874290C (en) 2012-06-12 2020-02-25 Ferrosan Medical Devices A/S Dry haemostatic composition
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
CA2928963C (en) 2013-12-11 2020-10-27 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
CN106999621B (zh) 2014-10-13 2020-07-03 弗罗桑医疗设备公司 用于止血和伤口愈合的干组合物
US10653837B2 (en) 2014-12-24 2020-05-19 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
EP3316930B1 (en) 2015-07-03 2019-07-31 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
KR20210008479A (ko) 2018-05-09 2021-01-22 훼로산 메디칼 디바이스 에이/에스 지혈 조성물을 제조하는 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498599A (en) * 1994-01-21 1996-03-12 Amgen Inc. Methods for stimulating platelet production
YU34196A (sh) * 1995-06-07 1999-03-04 Glaxo Group Limited Peptidi i jedinjenja koja se vezuju za receptor
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999042127A2 (en) * 1998-02-24 1999-08-26 Receptron, Inc. Receptor derived peptides as modulators of receptor activity

Also Published As

Publication number Publication date
IL152204A0 (en) 2003-05-29
EP1278849A2 (en) 2003-01-29
EA006423B1 (ru) 2005-12-29
AU2001267366B9 (en) 2005-07-14
WO2001080873A2 (en) 2001-11-01
MXPA02010458A (es) 2003-06-06
GEP20063763B (en) 2006-03-10
US20030181659A1 (en) 2003-09-25
CZ20023517A3 (cs) 2003-10-15
KR20030009450A (ko) 2003-01-29
PL358304A1 (en) 2004-08-09
BR0110383A (pt) 2003-01-21
AR030278A1 (es) 2003-08-20
SK15262002A3 (sk) 2003-05-02
BG107214A (bg) 2003-11-28
EA200201138A1 (ru) 2003-06-26
ZA200208662B (en) 2003-10-27
EE200200610A (et) 2004-08-16
JP2003530867A (ja) 2003-10-21
EP1149906A1 (en) 2001-10-31
AU2001267366B2 (en) 2005-06-30
WO2001080873A3 (en) 2002-01-31
YU79202A (sh) 2006-01-16
NO20025114D0 (no) 2002-10-24
NO20025114L (no) 2002-12-18
AU6736601A (en) 2001-11-07
CA2407167A1 (en) 2001-11-01
CN1426467A (zh) 2003-06-25
HUP0300559A3 (en) 2005-09-28
IS6582A (is) 2002-10-14

Similar Documents

Publication Publication Date Title
HUP0300559A2 (hu) A trombopoietin receptort moduláló peptidek
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
HUP0402029A2 (hu) Peptidalapú multimer célzott kontrasztanyagok
HUP0303996A2 (hu) Vakcinakészítmények
HUP0302636A2 (hu) Hasított burkolt víruskészítmény
HUP0401978A2 (hu) Tamszulozintabletták
HUP0002196A2 (hu) Gyógyhatású táplálékkiegészítő cukorbetegek részére
ATE318590T1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
HUP0303656A2 (hu) Bruton-féle tirozin kináz modulátorai és Bruton-féle tirozin kináz intermedierek, és eljárások azonosításukra és alkalmazásuk oszteoporózis és rokon betegségek kezelésére és prevenciójára
HUP0003852A2 (hu) Erősen szelektív butiril-kolin-észteráz inhibitorok alkalmazása Alzheimer-kór és elmebaj kezelésére és diagnosztizálására
HUP0101317A2 (hu) Módosított VIII-as faktor
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
HUP0301349A2 (hu) IL-11-tartalmú készítmények
NO20004419D0 (no) Ny anvendelse
HUP0104647A2 (hu) Hatóanyagként tilidin-mezilátot tartalmazó, szabályozott hatóanyag-leadású gyógyszerkészítmény
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
HUP0303167A2 (hu) IB-alfa vérlemezke glikoproteinnel képzett fúziós polipeptidek, továbbá eljárások alkalmazásukra
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
HUP0002455A2 (hu) Gyomorban maradó gyógyszerészeti készítmény
HUP0302738A2 (hu) SARP-1 alkalmazása scleroderma kezelésére és megelőzésére
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
HUP0400191A2 (hu) Leheletszabályozó mikrokapszulák
AU2381402A (en) Small acid-soluble spore protein and uses thereof
HUP0302977A2 (hu) Daganatok és ezzel összefüggő fájdalmak kezelésére szolgáló endotelin antagonistákat tartalmazó gyógyszerkészítmény

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees